Rurik Joel Gregory, Le Phu Christian, Mustroph Julian, Buggert Marcus
Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm 17177, Sweden.
Department of Internal Medicine II (Cardiology), University Clinic Regensburg, Regensburg 93053, Germany.
Cardiol Plus. 2025 Apr-Jun;10(2):129-144. doi: 10.1097/CP9.0000000000000116. Epub 2025 Jun 24.
Cardiovascular diseases remain the leading cause of death worldwide. Despite significant progress and the development of numerous effective drugs, substantial morbidity and mortality persist. This review highlights one potentially fruitful avenue for discovering novel therapeutics: leveraging ribonucleic acid (RNA) to tip the immunological balance toward tissue repair. Decades of research have primed the three disciplines of cardiology, immunology, and RNA drug development, to bring potent intersectional therapies to the clinic. We discuss both coding and non-coding RNA interventions across multiple cell types, such as monocytes, macrophages, and T cells, throughout different cardiovascular diseases. Altogether, advanced RNA-based medicines targeting the immune system are primed to transform how cardiovascular diseases are treated.
心血管疾病仍然是全球主要的死亡原因。尽管取得了重大进展并开发了许多有效的药物，但仍存在大量的发病和死亡情况。本综述强调了一条发现新型疗法的潜在有效途径：利用核糖核酸（RNA）使免疫平衡向组织修复倾斜。数十年的研究为心脏病学、免疫学和RNA药物开发这三个学科做好了准备，以便将强大的交叉疗法引入临床。我们讨论了在不同心血管疾病中，针对多种细胞类型（如单核细胞、巨噬细胞和T细胞）的编码和非编码RNA干预措施。总之，针对免疫系统的先进RNA药物有望改变心血管疾病的治疗方式。
